Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?

Detalles Bibliográficos
Autores principales: Gravara, Luigi Della, Battiloro, Ciro, Cantile, Rosa, Letizia, Antonietta, Vitiello, Fabiana, Montesarchio, Vincenzo, Rocco, Danilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110571/
https://www.ncbi.nlm.nih.gov/pubmed/32256708
http://dx.doi.org/10.2217/lmt-2019-0018
_version_ 1783513074404163584
author Gravara, Luigi Della
Battiloro, Ciro
Cantile, Rosa
Letizia, Antonietta
Vitiello, Fabiana
Montesarchio, Vincenzo
Rocco, Danilo
author_facet Gravara, Luigi Della
Battiloro, Ciro
Cantile, Rosa
Letizia, Antonietta
Vitiello, Fabiana
Montesarchio, Vincenzo
Rocco, Danilo
author_sort Gravara, Luigi Della
collection PubMed
description
format Online
Article
Text
id pubmed-7110571
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-71105712020-04-02 Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? Gravara, Luigi Della Battiloro, Ciro Cantile, Rosa Letizia, Antonietta Vitiello, Fabiana Montesarchio, Vincenzo Rocco, Danilo Lung Cancer Manag Editorial Future Medicine Ltd 2020-02-12 /pmc/articles/PMC7110571/ /pubmed/32256708 http://dx.doi.org/10.2217/lmt-2019-0018 Text en © 2020 Luigi Della Gravara et al. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Editorial
Gravara, Luigi Della
Battiloro, Ciro
Cantile, Rosa
Letizia, Antonietta
Vitiello, Fabiana
Montesarchio, Vincenzo
Rocco, Danilo
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title_full Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title_fullStr Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title_full_unstemmed Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title_short Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
title_sort chemotherapy and/or immune checkpoint inhibitors in nsclc first-line setting: what is the best approach?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110571/
https://www.ncbi.nlm.nih.gov/pubmed/32256708
http://dx.doi.org/10.2217/lmt-2019-0018
work_keys_str_mv AT gravaraluigidella chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT battilorociro chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT cantilerosa chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT letiziaantonietta chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT vitiellofabiana chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT montesarchiovincenzo chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach
AT roccodanilo chemotherapyandorimmunecheckpointinhibitorsinnsclcfirstlinesettingwhatisthebestapproach

Ejemplares similares